<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659031</url>
  </required_header>
  <id_info>
    <org_study_id>ABC008-IBM-101</org_study_id>
    <nct_id>NCT04659031</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)</brief_title>
  <official_title>A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abcuro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abcuro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, ascending dose study for adult patients with inclusion body myositis (IBM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Safety and Tolerability</measure>
    <time_frame>Through Study Completion an average of 28 weeks</time_frame>
    <description>Characterize the safety and tolerability profile of escalating dose levels of ABC008 in IBM when administered subcutaneously (SC) as measured by the number and severity of treatment emergent adverse events, serious adverse events, and adverse events of special interest, number of dose limiting toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of peak serum concentration (Cmax)</measure>
    <time_frame>Day 1 and throughout the 24 weeks of follow up</time_frame>
    <description>Assess the peak serum concentration (Cmax) of a single dose of ABC008</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of time to peak serum concentration (Tmax)</measure>
    <time_frame>Day 1 and throughout the 24 weeks of follow up</time_frame>
    <description>Assess the time to peak serum concentration (Tmax) of a single dose of ABC008</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of terminal half-life (t½)</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess the terminal half-life (t½) of ABC008</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of area under the concentration versus time curve from time zero to 24 hours post-dose (AUC0-24hr)</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess the area under the concentration versus time curve of a single dose of ABC008 from time zero to 24 hours post-dose (AUC0-24hr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of apparent clearance (CL/F)</measure>
    <time_frame>Day 1 and throughout the 24 weeks of follow up</time_frame>
    <description>Assessment of apparent clearance (CL/F) of a single dose of ABC008</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1 and throughout the 24 weeks of follow up</time_frame>
    <description>Assessment of apparent volume of distribution (Vz/F) of a single dose of ABC008</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of changes in KLRG1 expressing lymphocytes</measure>
    <time_frame>Day 1 and throughout the 24 weeks of follow up</time_frame>
    <description>Characterize changes in KLRG1 expressing lymphocytes</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Inclusion Body Myositis</condition>
  <arm_group>
    <arm_group_label>Cohort D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>X.X mg / kg ABC008</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>X.X mg / kg ABC008</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>X.X mg / kg ABC008</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>X.X mg / kg ABC008</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tbd (if an alternative dose cohort is needed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC008</intervention_name>
    <description>ABC008</description>
    <arm_group_label>Cohort D1</arm_group_label>
    <arm_group_label>Cohort D2</arm_group_label>
    <arm_group_label>Cohort D3</arm_group_label>
    <arm_group_label>Cohort D4</arm_group_label>
    <arm_group_label>Cohort D5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of either clinico-pathologically defined IBM, clinically defined IBM, or&#xD;
             probable IBM according to the European Neuromuscular Center (ENMC) IBM 2011&#xD;
&#xD;
          -  Able to arise from a chair (with or without armrests) without support from another&#xD;
             person or device&#xD;
&#xD;
          -  Able to ambulate at least 20 feet / 6 meters with or without assistive device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking &gt; 7.5 mg prednisolone (or equivalent) or on intravenous immunoglobulin (IVIg)&#xD;
             or other immunosuppressants within the last 3 months. Topical, nasal, and ocular&#xD;
             corticosteroids are allowed unless they are being widely applied or the severity of&#xD;
             the underlying condition makes them unsuitable in the Investigator's opinion. Local&#xD;
             steroid injections are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angela Skipper</last_name>
    <phone>617-766-5908</phone>
    <email>ASkipper@hallorancg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Birkin</last_name>
    </contact>
    <investigator>
      <last_name>Roula Ghaoui, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perron Institute</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Walters</last_name>
    </contact>
    <investigator>
      <last_name>Merilee Needham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inclusion Body Myositis</keyword>
  <keyword>IBM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

